Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villeurbanne – page 152

2 127 clinical trials in Villeurbanne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villeurbanne at a glance
2 127
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 127 trials in Villeurbanne

Open in trial search

Rhabdomyosarcoma+4

Not recruiting

Study of Lenvatinib for Children and Young Adults with Relapsed or Refractory Solid Tumors, Including High Grade Glioma and Rhabdomyosarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Chronic kidney disease+1

Not recruiting

Study on Low Dose Rivaroxaban for Heart and Blood Vessel Disease in Patients with Advanced Kidney Disease or on Dialysis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:The George Institute For Global Health

Study of Entrectinib in Children and Adolescents with Advanced or Metastatic Solid Tumors or Primary CNS Tumors with No Satisfactory Treatment Options

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Malignant melanoma+1

Not recruiting

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Parkinson's disease

Not recruiting

Study on the Long-Term Safety of ND0612 (Carbidopa, Levodopa) Infusion for Patients with Advanced Parkinson's Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Neuroderm Ltd.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Villeurbanne

What the registry says about research in the country

01 Neurodegenerative Diseases

Extensive research focusing on Alzheimer's disease treatments, including multiple studies evaluating novel therapeutic approaches for early-stage patients. Additional investigations examine Parkinson's disease and serotonergic receptor expression.

  • Early Alzheimer's Disease Interventions
  • Parkinson's Disease Mechanisms
  • Cognitive Function Assessment

Studies utilize innovative compounds and treatment strategies to address disease progression and symptoms.

02 Cardiovascular Health

Innovative research targeting heart failure prevention through combination therapy approaches. Studies evaluate new treatment strategies for reducing cardiovascular risks and improving patient outcomes.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Combined Therapeutic Approaches

Focus on preventive strategies and risk reduction in high-risk populations.

03 Oncology Research

Comprehensive studies in various cancer types, including colorectal cancer, breast cancer, and gastric cancer. Research emphasizes personalized treatment approaches and innovative therapeutic strategies.

  • Colorectal Cancer Treatment
  • Breast Cancer Hormone Therapy
  • Gastrointestinal Oncology

Trials incorporate advanced diagnostic methods and targeted therapies.

04 Respiratory Medicine

Studies examining treatments for severe asthma and COPD, evaluating new therapeutic combinations and investigating treatment responses in respiratory conditions.

  • Asthma Management
  • COPD Interventions
  • Respiratory Treatment Optimization

Focus on improving pulmonary outcomes and patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.